Datta Niloy R, Puric Emsad, Heüberger Juerg, Marder Dietmar, Lomax Nicoletta, Timm Olaf, Memminger Priska, Bodis Stephan
RadioOnkologieZentrum, KSA-KSB, Kantonsspital Aarau, Switzerland.
RadioOnkologieZentrum, KSA-KSB, Kantonsspital Aarau, Switzerland and Department of Radiation Oncology, University Hospital Zurich, Switzerland.
Swiss Med Wkly. 2015 Apr 23;145:w14133. doi: 10.4414/smw.2015.14133. eCollection 2015.
The aim of this retrospective analysis was to evaluate the safety and efficacy of local hyperthermia (HT) and reirradiation (ReRT) in the management of preirradiated locoregional recurrent breast cancers at Kantonsspital Aarau, Switzerland.
Twenty-four previously irradiated patients who had developed locoregional recurrences in the chest wall or breast, with or without regional lymph node involvement, were reirradiated to a mean dose of 36.8 Gy (range 20-50 Gy) delivered at a mean dose per fraction of 2.33 Gy (range 1.8-4.0 Gy). All patients received local HT at 41 to 43 °C, once or twice a week prior to radiotherapy. Online thermometry was carried out during the hyperthermia sessions.
An overall objective response rate of 91.7% (22/24) with a complete response in 66.7% (16/24) of patients and partial response in 25% (6/24) of patients was observed. Post-thermoradiotherapy follow-up ranged from 1 to 38 months (median 10 months). The 3-year actuarial local control rate was 59.7%. More patients who attained complete response had sustained locoregional control until their death or last follow-up when compared with those who were partial or non-responders (median local disease-free survival for complete responders not reached; for partial and non-responders 4 months; p <0.001). Post-retreatment median overall survival for all 24 patients was 10 months. Grade III/IV acute toxicity was seen in only one patient and no patient had any significant late morbidity.
ReRT and HT is an effective and a safe modality to treat locoregional recurrences in previously irradiated breast cancers. The approach can lead to sustainable long-term palliation with minimal morbidity.
本回顾性分析的目的是评估在瑞士阿劳州立医院,局部热疗(HT)和再程放疗(ReRT)用于治疗曾接受过放疗的局部区域复发性乳腺癌的安全性和有效性。
24例先前接受过放疗且出现胸壁或乳腺局部区域复发的患者,无论有无区域淋巴结受累,均接受再程放疗,平均剂量为36.8 Gy(范围20 - 50 Gy),每次分割剂量平均为2.33 Gy(范围1.8 - 4.0 Gy)。所有患者在放疗前每周接受1次或2次41至43°C的局部热疗。热疗期间进行在线体温测量。
观察到总体客观缓解率为91.7%(22/24),其中完全缓解率为66.7%(16/24),部分缓解率为25%(6/24)。热放疗后的随访时间为1至38个月(中位时间10个月)。3年精算局部控制率为59.7%。与部分缓解或无缓解的患者相比,达到完全缓解的患者在死亡或最后一次随访前维持局部区域控制的时间更长(完全缓解者的局部无病生存期未达到中位值;部分缓解和无缓解者为4个月;p<0.001)。所有24例患者治疗后的中位总生存期为10个月。仅1例患者出现III/IV级急性毒性反应,无患者出现任何严重的晚期并发症。
再程放疗和热疗是治疗先前接受过放疗的乳腺癌局部区域复发的一种有效且安全的方式。该方法能以最小的发病率实现可持续的长期姑息治疗。